NO168645B - Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-6-(2-(3-eller 4-karboksamido-substituert-pyrrol-1-yl)alkyl)-4-hydroksypyran-2-on-derivater - Google Patents
Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-6-(2-(3-eller 4-karboksamido-substituert-pyrrol-1-yl)alkyl)-4-hydroksypyran-2-on-derivater Download PDFInfo
- Publication number
- NO168645B NO168645B NO872259A NO872259A NO168645B NO 168645 B NO168645 B NO 168645B NO 872259 A NO872259 A NO 872259A NO 872259 A NO872259 A NO 872259A NO 168645 B NO168645 B NO 168645B
- Authority
- NO
- Norway
- Prior art keywords
- pyrrole
- preparation
- alkyl
- hydroxy
- ethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims description 16
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- -1 pyrrol-l-yl Chemical group 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 150000002596 lactones Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 239000012442 inert solvent Substances 0.000 claims description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 150000001261 hydroxy acids Chemical class 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- NBRUYSABHAXNLL-ZEQRLZLVSA-N 5-(4-fluorophenyl)-1-[2-[(2s,4s)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-(trifluoromethyl)pyrrole-3-carboxamide Chemical compound O1C(=O)C[C@@H](O)C[C@@H]1CCN1C(C(F)(F)F)=C(C(=O)NC=2C=CC=CC=2)C(C=2C=CC=CC=2)=C1C1=CC=C(F)C=C1 NBRUYSABHAXNLL-ZEQRLZLVSA-N 0.000 claims description 3
- OUCSEDFVYPBLLF-SVBPBHIXSA-N 5-(4-fluorophenyl)-1-[2-[(2s,4s)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H]2OC(=O)C[C@@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-SVBPBHIXSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Chemical group 0.000 claims description 3
- 239000000460 chlorine Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- SMBQBQBNOXIFSF-UHFFFAOYSA-N dilithium Chemical compound [Li][Li] SMBQBQBNOXIFSF-UHFFFAOYSA-N 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- VVNXEADCOVSAER-UHFFFAOYSA-N lithium sodium Chemical compound [Li].[Na] VVNXEADCOVSAER-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- CMHHITPYCHHOGT-UHFFFAOYSA-N tributylborane Chemical compound CCCCB(CCCC)CCCC CMHHITPYCHHOGT-UHFFFAOYSA-N 0.000 claims description 3
- HSGOCVTUBJPSLD-ZEQRLZLVSA-N 2-(4-fluorophenyl)-1-[2-[(2s,4s)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-5-(trifluoromethyl)pyrrole-3-carboxamide Chemical compound O1C(=O)C[C@@H](O)C[C@@H]1CCN1C(C(F)(F)F)=C(C=2C=CC=CC=2)C(C(=O)NC=2C=CC=CC=2)=C1C1=CC=C(F)C=C1 HSGOCVTUBJPSLD-ZEQRLZLVSA-N 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 24
- 239000002253 acid Substances 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 13
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 abstract description 10
- 235000012000 cholesterol Nutrition 0.000 abstract description 10
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract description 6
- 150000007513 acids Chemical class 0.000 abstract description 5
- 239000003529 anticholesteremic agent Substances 0.000 abstract description 5
- 239000003524 antilipemic agent Substances 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 abstract description 4
- 230000000055 hyoplipidemic effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 150000003233 pyrroles Chemical class 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical compound C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 description 3
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical group O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006352 cycloaddition reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000000871 hypocholesterolemic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229940057061 mevalonolactone Drugs 0.000 description 3
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 3
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000001462 1-pyrrolyl group Chemical class [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VHFAMHWIQKTZMV-UHFFFAOYSA-N 5-(4-Fluorophenyl)-2-(1-methylethyl)-1-(3-oxopropyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 VHFAMHWIQKTZMV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000005518 carboxamido group Chemical group 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- RVNDDFOOGMHHRS-UHFFFAOYSA-N n,3-diphenylprop-2-ynamide Chemical compound C=1C=CC=CC=1C#CC(=O)NC1=CC=CC=C1 RVNDDFOOGMHHRS-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical class OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- IXMMBPWOHZOEEQ-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-(3-oxopropyl)-n,4-diphenyl-5-(trifluoromethyl)pyrrole-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(N(C(=C1C=2C=CC=CC=2)C(F)(F)F)CCC=O)=C1C(=O)NC1=CC=CC=C1 IXMMBPWOHZOEEQ-UHFFFAOYSA-N 0.000 description 1
- QEZWMCGZNVHQBS-UHFFFAOYSA-N 2-[2-(1,3-dioxolan-2-yl)ethyl-(2-methylpropanoyl)amino]-2-(4-fluorophenyl)acetic acid Chemical compound C=1C=C(F)C=CC=1C(C(O)=O)N(C(=O)C(C)C)CCC1OCCO1 QEZWMCGZNVHQBS-UHFFFAOYSA-N 0.000 description 1
- WMHRYMDGHQIARA-UHFFFAOYSA-N 4-hydroxyoxan-2-one Chemical class OC1CCOC(=O)C1 WMHRYMDGHQIARA-UHFFFAOYSA-N 0.000 description 1
- VNZOLPIHDIJPBZ-UHFFFAOYSA-N 4-hydroxypyran-2-one Chemical group OC=1C=COC(=O)C=1 VNZOLPIHDIJPBZ-UHFFFAOYSA-N 0.000 description 1
- UBECAZBDNZHVRY-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(3-oxopropyl)-n,4-diphenyl-2-(trifluoromethyl)pyrrole-3-carboxamide Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CC=CC=2)C(C(=O)NC=2C=CC=CC=2)=C(C(F)(F)F)N1CCC=O UBECAZBDNZHVRY-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N mevalonic acid Chemical compound OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Description
Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av forbindelser egnet som hypokolestrolemiske og hypolipidemiske midler. Mer spesielt er det tale om en fremgangsmåte for fremstilling av visse trans-6-[2-(3- eller 4-karboksamido-substituert-pyrrol-l-yl)alkyl]-4-hydroksypyran-2-oner og de korresponderende ringåpnede syrer oppnådd fra disse, og som er potente inhibitorer av enzymet 3-hydroksy-3-metylglutaryl-koenzym-A-reduktase (HMG CoA reduktase), og som kan anvendes for inhibering av biosyntese av kolesterol.
Høye nivå av kolesterol og blodlipider i blod er tilstander som inngår ved begynnende arteriosklerose. Det er velkjent at inhibitorer av HMG CoA reduktase senker nivået av blodplasma-kolesterol, spesielt low density lipoprotein kolesterol (LDL-C) hos mennesket (se M. S. Brown & J. L. Goldstein, New England Journal of Medicine, 305, nr. 9, 515-517 (1981). Det er nå fastslått at senkning av LDL-C nivået gir beskyttelse mot koronar hjertesykdom (se Journal of the American Medical Association, 251, nr. 3, 351-374 (1984).
Det er dessuten kjent at enkelte derivater av mevalonsyre (3,5-dihydroksy-3-metylpentansyre) og den korresponderende cykliserte laktonform, mevalonolakton, inhiberer biosyntesen av kolesterol (se F. M. Singer et al., Proe. Soc. Exper. Biol. Med., 102: 270 (1959) og F. H. Hulcher, Arch. Biochem. Biophys., 146: 422 (1971)).
US-patent 3.983.140; 4.049.495 og 4.137.322 beskriver den enzymatiske produksjon av et naturlig produkt som nå kalles compactin, som har en inhiberende virkning på kolesterolets biosyntese. Compactin er vist å ha en kompleks struktur som innbefatter en mevalonolakton-del (Brown et al, J. Chem. Soc. Perkin I (1976) 1165.
US-patent 4.255.444 beskriver flere syntetiske derivater
av mevalonolakton som har antilipidemisk aktivitet.
US-patent 4.198.425 og 4.262.013 beskriver aralkyl-derivater av mevalonolakton som er egnet for behandling av hyper1ipidemi.
US-patent 4.375.475 beskriver enkelte substituerte 4-hydroksytetrahydropyran-2-oner som i den 4(R)-trans-stereoisomere form er inhibitorer av kolesterol biosyntese.
Publisert PCT-søknad W.O 84/02131 beskriver visse indol-analoger og derivater av mevalonolakton som har anvendelse som hypolipoproteinemiske og antiaterosklerotiske midler.
I henhold til foreliggende oppfinnelse fremstilles visse trans-6-[2-(3 eller 4-karboksamido-substituert pyrrol-1-yl)alkyl]-4-hydroksypyran-2-oner og de korresponderende ringåpnede hydroksysyrer oppnådd fra disse, som er potente inhibitorer av kolesterol biosyntese som følge av deres evne til å inhibere enzymet 3-hydroksy-3-metylglutaryl-koenzym A reduktase (HMG-CoA reduktase).
Oppfinnelsen angår en fremgangsmåte for fremstilling av forbindelser med strukturformel I
hvor X er -CH2-, -CH2-CH2-, -CH2CH2CH2- eller -CH2CH(CH3)-.
Ri er fenyl substituert med fluor, klor eller brom; trifluormetyl; eller alkyl med 1-4 karbonatomer.
Den ene av R2 eller R3 er -CONHPh, og den andre er
fenyl. (Ph betyr her over alt fenyl).
R4 er alkyl med 1-6 karbonatomer eller trifluormetyl.
Ålment tilgjengelig norsk patentansøkning 85.3725 angår forbindelser som ligner på forbindelsene som fremstilles ifølge foreliggende oppfinnelse, men de inneholder ikke gruppen
-CONHPh som er til stede i 3- eller 4- stilling i forbindelsene fremstilt ifølge foreliggende oppfinnelse. Det har vist seg at denne gruppe medfører en betydelig forbedring av forbindelsenes virkning. Innenfor rammen av foreliggende oppfinnelse faller også fremstillingen av hydroksysyrer og farmasøytisk akseptable salter derav, som er oppnådd ved åpning av laktonringen av forbindelser med den ovenfor angitte strukturformel I. Fremgangsmåten for fremstilling av forbindelser med strukturformel I omfatter a) omsetning av en substituert [(pyrrol-l-yl)alkyl]aldehyd-forbindelse med formel
med dilitium eller natrium-litiumsaltet av metylacetoacetat for å danne en forbindelse med strukturen b) reduksjon av produktet fra trinn a) med en trialkylboran-forbindelse, så som tributylboran i nærvær av natriumborhydrid i et inert oppløsningsmiddel; c) oksydasjon av produktet fra trinn b) med alkalisk vandig hydrogenperoksydoppløsning for å gi en forbindelse med formel
og
d) cyklisering av produktet fra trinn c) til et lakton med formel I ved oppvarming i et inert oppløsningsmiddel så som
toluen, eller alternativt, ved omdannelse av produktet fra trinn c) til et farmasøytisk akseptabelt salt etter konvensjonelle metoder.
Farmasøytiske preparater egnet som: hypolipidemiske eller hypokolesterolemiske midler omfatter, en hypolipidemisk eller hypokolesterolemisk virksom mengde' av en forbindelse fremstillet i henhold til oppfinnelsen i kombinasjon med et farmasøytisk akseptabelt bæremiddel. En måte å inhibere kolesterol biosyntesen hos en pasient på, består i å gi en. virksom mengde av et farmasøytisk preparat av ovenfor omtalte type.
Forbindelsene fremstillet i henhold til foreliggende oppfinnelse omfatter en klasse av trans-6-[2-(3- eller 4-karboksamido-substituert pyrrol-l-yl)alkyl]4-hydroksypyran-2-oner hvor pyran-2-on-delen er tilknyttet via en alkylkjede til nitrogenatomet i den substituerte pyrrolkjerne eller i 1-stillingen. Alkylgruppen kan være metylen, etylen, propylen eller metyletylen. Den foretrukne alkylkjede som knytter sammen den substituerte pyrrolkjerne og 4-hydroksypyran-2-on-ringen er etylen.
Forbindelser med strukturformel I har 2 asymmetriske karbonsentra, det ene i pyran-2-on-ringens 4-hydroksystilling og det andre i pyran-2-on-ringens 6-stilling, hvor alkylpyrrol-gruppen er tilknyttet. Denne asymmetri gir mulighet for fire isomerer, hvorav to er R-cis- og S-cis-isomerene og de andre to er R-trans- og S-trans-isomerene. Foreliggende oppfinnelse gjelder bare trans-formen av forbindelsene I.
I forbindelser fremstillet i henhold til oppfinnelsen er 2-stillingen i den substituerte pyrrolkjerne substituert med fenyl substituert med fluor, klor eller brom; trifluormetyl eller alkyl med 1-4 karbonatomer.
I forbindelser fremstillet i henhold til oppfinnelsen er 5-stillingen i pyrrolkjernen substituert med alkyl med 1-6 karbonatomer eller trifluormetyl. En foretrukket substituent er isopropyl.
Den foretrukne syntese for fremstilling av de nye forbindelser består i cykloaddisjon av et di-substituert acetylen, hvor en substituent er karboksamido eller N-substituert karboksamido, til en passende substituert N-acylaminokarboksyl-syre for å danne et substituert pyrrol. Denne addisjon kan skje på én av to måter som fører til et substituert pyrrol-addisjonsprodukt hvor karboksamido-substituenten sitter enten på karbon 3 eller karbon 4 i pyrrolkjernen.
I forbindelser fremstillet i henhold til oppfinnelsen er substituenten i 3- eller 4-stillingen i pyrrolkjernen -CONHPh, og den andre av de to stillingene er substituert med fenyl.
Utgangsforbindelsene for foreliggende fremgangsmåte kan fremstilles etter det generelle reaksjonsskjema som er vist i Reaksjonsskjerna 1 som utnytter den type kjemi av mes-ioniske forbindelser som opprinnelig er beskrevet av R. Huisgen et al., Ang. Chem. Int. Ed., 3: 136 (1964).
De kjente, eller lett syntetiserbare a-halogenestere med strukturformel II omsettes med det kjente 2-[1-(2-aminoalkyl)]-1,3-dioksalan, III, i nærvær av et syreoppfangende middel så som trietylamin for å gi N-alkyl-ot-aminoestere IV. Aminoesterne IV acyleres med et syrehalogenid og hydrolyseres deretter i en vandig basisk oppløsning for å gi N-acyl-N-alkylaminosyrene V.
N-acyl-N-alkylaminosyrene V omsettes med en passende substituert karboksamido-acetylen-forbindelse VI i nærvær av et syreanhydrid for å gi en blanding av de isomere substituerte pyrrol-forbindelsene Vila og Vllb. Avhengig av de forekommende substituenter, gir denne cyklo-addisjonsreaksjon varierende forhold mellom de to produktene. Når for eksempel R4 er trifluormetyl, gir reaksjonen noenlunde ekvimolare mengder av de to isomere produktene. I slike situasjoner adskilles de to isomere produktene ved velkjent kromatografisk teknikk, hvorpå de eventuelt renses ytterligere ved omkrystallisasjon. Når R4 derimot er 1-metyletyl, gir cyklo-addisjonsreaksjonen hovedsakelig ett produkt som kan renses ved omkrystallisasjon alene.
Hydrolyse av acetalfunksjonen i forbindelsene Vila og Vllb i vandig sur oppløsning fører til aldehydene Villa og Vlllb. Aldehydene VIII omsettes i henhold til oppfinnelsen etter den fremgangsmåte som er skissert i Reaksjonsskjema 2. Aldehyd-forbindelsene VIII, omsettes med dilitium eller litium-natrium-saltet av metylacetoacetat for å gi de korresponderende 7-(substituert-pyrrolyl)-5-hydroksy-3-oksoheptanoater, IX. Heptanoatene, IX, oppløses i et polart oppløsningsmiddel så som tetrahydrofuran som det på forhånd er boblet gjennom små mengder luft. Et svakt overskudd av et trialkylboran, så som tributylboran, tilsettes blandingen som så avkjøles til en temperatur på mellom 0°C og -78°C, hvoretter natriumborhydrid tilsettes. Blandingen omrøres i ca. 1-2 timer og oksyderes deretter ved tilsetning av basisk vandig hydrogenperoksydopp-løsning. Reaksjonen fører til 7-(substituert-pyrrolyl)-3,5-dihydroksyheptansyrer, X, hvor produktet hovedsakelig inneholder den ønskede forbindelse med R<*>,R<*> konfigurasjon i karbonatomene 3 og 5 som bærer hydroksygruppene.
Syrene kan eventuelt på konvensjonell måte omdannes til et korresponderende farmasøytisk akseptabelt salt eller cykliseres til trans-6-[2-(substituert-pyrrol-l-yl)alkyl]pyran-2-on-forbindelsene, I, ved dehydrering i et inert oppløsningsmiddel, så som kokende toluen under azeotropisk fjerning av vann. Dette cykliseringstrinn har vist seg å føre til materiale som inneholder 85-90% av den ønskede trans-konfigurasjon i 4-hydroksygruppen i forhold til 6-(substituert-pyrrol-l-yl)alkylgruppen i pyran-2-on-lakton-ringen.
De ringåpnede hydroksysyrene med strukturformel Xa og Xb er mellomprodukter ved syntese av lakton-forbindelsene I og kan benyttes i form av deres frie syrer eller i form av et farma-søytisk akseptabelt metall- eller amin-salt i farmasøytiske preparater. Disse syrene reagerer under dannelse av farmasøytisk akseptable metall- eller amin-salter. Uttrykket "farmasøytisk akseptable metallsalt" skal omfatte salter dannet med natrium-, kalium-, kalsium-, magnesium-, aluminium-, jern- og sink-ioner. Uttrykket "farmasøytisk akseptable aminsalter" skal omfatte salter med ammoniakk og organiske nitrogenholdige baser som er tilstrekkelig sterke til å danne salter med karboksylsyrer. Den frie syreform av forbindelser fremstillet i henhold til oppfinnelsen kan om ønskes, regenereres fra saltformen ved å bringe saltet i kontakt med en fortynnet vandig oppløsning av en syre så som saltsyre.
Baseaddisjonssalter kan være forskjellig fra den frie syreform med hensyn til fysikalske egenskaper som oppløselighet og smeltepunkt, men ansees ellers i denne sammenheng som likeverdige med den frie syreform.
Forbindelsene fremstillet i henhold til oppfinnelsen kan forekomme i solvatisert eller usolvatisert form. I alminnelighet er de solvatiserte former med farmasøytisk akseptable opp-løsningsmidler så som vann, etanol og lignende, i denne henseende likeverdige med de usolvatiserte former.
Forbindelsene fremstillet i henhold til oppfinnelsen kan benyttes som hypokolesterolemiske eller hypolipidemiske midler på grunn av deres evne til å inhibere biosyntesen av kolesterol gjennom inhibering av enzymet 3-hydroksy-3-metylglutaryl-koenzym A reduktase (HMG-CoA reduktase).
Forbindelsenes evne til å inhibere biosyntesen av kolesterol ble målt etter to metoder. Den første metode (betegnet CSI selektering) gjør bruk av fremgangsmåten beskrevet av R. E. Dugan et al., Archiv. Biochem. Biophys., (1972), 152 21-27. Etter denne metode økes nivået av HMG-CoA enzymaktiviteten i standard laboratorierotter ved å fore dyrene med en "chow" diett inneholdende 5% kolestyramin i 4 dager før avlivning av rottene.
Rotteleverne ble homogenisert, og inkorporeringen av kolesterol-<14>C-acetat i uforsåpbart lipid gjennom rottelever-homogenatet ble målt. Den konsentrasjon av forbindelsen, uttrykt i mikromol, som var nødvendig for 50% inhibering av sterolsyntesen over et tidsrom på 1 time ble målt og uttrykt som en IC50<->verdi.
Den andre metoden (betegnet COR selektering) benytter seg av fremgangsmåten beskrevet av T. Kita et al., J. Clin. Invest., (198 0), 66: 1094-1100. Etter denne metode ble mengden av <14>C-HMG-CoA omdannet til <14>C-mevalonat i nærvær av et renset enzympreparat av HMG-CoA reduktase målt. Den konsentrasjon av forbindelsen, uttrykt i mikromol, som var nødvendig for 50% inhibering av kolesterolsyntesen, ble målt og angitt som en IC5o-verdi. Resultatene oppnådd med to forbindelser fremstilt ifølge oppfinnelsen sammenlignet med fire forbindelser beskrevet i NO-A 85.3725 er vist i tabell I.
Aktiviteten av flere representative eksempler på forbindelser fremstillet i henhold til oppfinnelsen, fremgår av Tabell II i sammenligning med den tidligere kjente forbindelse, compactin.
Ved terapeutisk anvendelse som hypolipidemiske eller hyppokolesterolemiske midler gis forbindelsene til pasienten i doseringer på 40-600 mg per dag. For en vanlig voksen person på ca. 70 kg legemsvekt utgjør dette en dosering på 0,5-8,0 mg/kg legemsvekt per dag.
Doseringen kan imidlertid varieres avhengig av pasientens behov, lidelsens grad og av hvilken forbindelse som benyttes.
De etterfølgende eksempler illusterer oppfinnelsen.
Eksempel 1
Fremstilling av trans- 5-( 4- fluorfenyl)- 2-( 1- metyletyl)- N. 4-difenyl- 1- f 2-( tetrahvdro- 4- hydroksy- 6- okso- 2H- pyran- 2- yl)-etyl1- pyrrol- 3- karboksamid
Trinn A. Fremstilling av a-[[2-(l,3-dioksalan-2-yl)etyl]-amino]-4-fluorbenzeneddiksyre, etylester
En oppløsning av 26 g (220 mmol) 2-[1-(2-aminoetyl)]-1,3-dioksalan i 50 ml acetonitril ble under omrøring ved romtemperatur tilsatt til en oppløsning av 200 mmol a-brom-4-fluorbenzeneddiksyre, etylester (J. W. Epstein et al., J. Med. Chem., 24: 481-490 (1981)) og 42 ml (300 mmol) trietylamin i 3 50 ml acetonitril. Den resulterende blanding ble omrørt ved romtemperatur over natten og deretter helt over i 500 ml dietyleter. Den resulterende suspensjon ble ekstrahert med 300 ml vann og deretter to ganger med 3 00 ml porsjoner 2M saltsyre. De kombinerte ekstraktene ble gjort basiske med 25% vandig natriumhydroksydoppløsning og ekstrahert to ganger med 500 ml porsjoner etylacetat. Etylacetatekstraktene ble kombinert, vasket suksessivt med vann og saltvann og deretter tørket over vannfri magnesiumsulfat. Tørkemidlet ble fjernet ved filtrering og residuet konsentrert for å gi 49,5 g a-[[2-(1,3-dioksalan-2-yl)etyl]amino]-4-fluorbenzeneddiksyre, etylester.
Det 9 0 MHz protonmagnetiske resonansspektrum av produktet
i deuterokloroform oppviste signaler ved 1,18 (triplett, 3H, J=7Hz); 1,85 (multiplett, 2H); 2,20 (bred singlett, 1H); 2,6 (multiplett, 2H); 3,85 (multiplett, 4H); 4,1 (kvartett, 2H, J=7Hz); 4,22 (singlett, 1H); 4,83 (triplett, 1H, J=4,5Hz); og 6,8-7,3 (multiplett, 4H) ppm mot lavere felt fra tetrametylsilan.
Trinn B. Fremstilling av a-[[2-(1,3-dioksolan-2-yl)etyl]-(2-metyl-l-oksopropyl)amino]-4-fluorbenzeneddiksyre, etylester.
30 g (100 mmol) a-[[2-(l,3-dioksalan-2-yl)etyl]amino]-4-fluorbenzeneddiksyre, etylester fra Trinn A ble oppløst i 200 ml diklormetån sammen med 28,6 ml (205 mmol) trietylamin, hvorpå den resulterende blanding ble avkjølt til 0°C under tørr nitrogen. En oppløsning av 11 ml (105 mmol) isobutyrylklorid i 50 ml diklormetån ble langsomt tilsatt under omrøring. Etter
fullført tilsetning ble blandingen omrørt i ytterligere 60 minutter og deretter helt over i 100 ml dietyleter. Eter-oppløsningen ble vasket suksessivt med porsjoner av vann, 2M saltsyre, natriumbikarbonatoppløsning og saltvann og deretter tørket over vannfri magnesiumsulfat. Fordampning av oppløsnings-midlene førte til 35 g av a-[[2-(1,3-dioksolan-2-yl)-etyl]-(2-metyl-l-oksopropyl)amino]-4-fluorbenzeneddiksyre, etylester.
Det 90 MHz protonmagnetiske resonansspektrum av en deuterokloroformoppløsning av produktet oppviste signaler ved 1,2 (multiplett, 9H); 1,7 (multiplett, 2H); 2,85 (multiplett, 1H); 3,35 (multiplett, 2H); 3,80 (multiplett, 4H); 4,20 (kvartett, 2H, J=7Hz); 4,60 (triplett, 1H, J=4,5Hz); 5,81 (singlett, 1H); og 6,8-7,3 (multiplett, 4H) ppm mot lavere felt fra tetrametylsilan.
Trinn C. Fremstilling av a-[[2-(1,3-dioksolan-2-yl)etyl]-(2-metyl-l-oksopropyl)amino]-4-fluorbenzeneddiksyre En oppløsning av 35 g (95,3 mmol) av esteren fra Trinn B og 12 g (300 mmol) natriumhydroksyd i 480 ml metanol:vann (5:1) ble oppvarmet under omrøring og tilbakeløpskjøling i 2 timer. Oppløsningen ble avkjølt til romtemperatur, konsentrert og fortynnet ved tilsetning av 500 ml vann. Den resulterende oppløsning ble ekstrahert med eter og det vandige lag surgjort med iskald 6M saltsyre og deretter ekstrahert to ganger med 300 ml porsjoner etylacetat.
. De kombinerte ekstraktene ble vasket med saltvann, tørket over vannfri magnesiumsulfat og inndampet for å gi 30 g rå a-
[[2-(1,3-dioksolan-2-yl)etyl]-(2-metyl-l-oksopropyl)amino]-4-fluorbenzeneddiksyre som ble benyttet uten videre rensing.
Det 90 MHz protonmagnetiske resonansspektrum av en deuterokloroformoppløsning av produktet oppviste signaler ved 1,11 (dublett, 6H, J=7Hz); 1,4-1,9 (multiplett, 2H); 2,85 (multiplett, 1H); 3,32 (multiplett, 2H) ; 3,75 (multiplett, 4H); 4,52 (triplett, 1H, J=4,5Hz); 5,73 (singlett, 1H); og 6,8-7,3 (multiplett, 4H) ppm mot lavere felt fra tetrametylsilan.
Trinn D. Fremstilling av N,3-difenylpropynamid
En oppløsning av 171 mmol dicykloheksylkarbodiimid i
250 ml diklormetån ble i løpet av 2 timer ved 0°C dråpevis tilsatt til en suspensjon av 171 mmol propiolsyre, 179,6 mmol anilin og 5 mmol 4-dimetylaminopyridin i 400 ml diklormetån. Etter fullført tilsetning ble blandingen omrørt i ytterligere 30 minutter og deretter fortynnet med dietyleter. Den resulterende blanding ble filtrert gjennom silikagel, konsentrert og residuet omkrystallisert for å gi 30,5 g N,3-difenyl-2-propynamid, smp. 122-123°C.
Analyse beregnet for C15<H>13NO:
Beregnet: C, 80,69%; H, 5,87%; N, 6,27%;
Funnet: C, 80,54%; H, 5,58%; N, 6,52%.
Infrarødt spektrum av en KBr pellet av forbindelsen oppviste hovedtopper ved 2215, 1630, 1595, 1549, 1490, 1445, 1330, 756 og 691 cm-<1>.
Trinn E. Fremstilling av l-[2-(l,3-dioksalan-2-yl)etyl]-5-(4-fluorfenyl)-2-(1-metyletyl)-N,4-difenyl-lH-pyrrol-3-karboksamid
En oppløsning av 95 g (280 mmol) oc-[ [2-(1,3-dioksolan-2-yl)etyl]-(2-metyl-l-oksopropyl)amino]-4-fluorbenzeneddiksyre, fremstillet som beskrevet i Trinn C og 98 g (439 mmol) N,2-difenylpropenkarboksamid, fremstillet som beskrevet i trinn D, ble oppvarmet til 90°C under omrøring i 4 timer (kraftig gassutvikling forekom i 2 timer). Etter dette tidsrom ble blandingen avkjølt til romtemperatur og kromatografert to ganger på silikagel under eluering med heksan:etylacetat (4:1) for å skille produktet (Rf=0,35) fra utgangsmaterialet (Rf=0,5).
Omkrystallisasjon av produktet fra isopropyleter førte til 59,5 g (119,3 mmol) 1-[2-(1,3-dioksalan-2-yl)etyl]-5-(4-fluorfenyl)-2-(1-metyletyl)-N,4-difenyl-lH-pyrrol-3-karboksamid, smp. 159-162°C.
Analyse for C31<H>31FN203:
Beregnet: C, 74,68%; H, 6,27%; N, 5,62%;
Funnet: C, 75,04%; H, 6,12%; N, 5,89%.
Trinn F. Fremstilling av 5-(4-fluorfenyl)-2-(1-metyletyl)-1-(3-oksopropyl)-N,4-difenyl-lH-pyrrol-3-karboksamid En oppløsning av 59 g (118,3 mmol) l-[2-(l,3-dioksalan-2-yl)etyl]-5-(4-fluorfenyl)-2-(1-metyletyl)-N,4-difenyl-lH-pyrrol-3-karboksamid fra Trinn E og 0,4 ml konsentrert saltsyre i 1200 ml vannfri etanol ble kokt under tilbakeløpskjøling og omrøring i 24 timer. Etter dette tidsrom ble blandingen avkjølt til romtemperatur, konsentrert og residuet tatt opp i 1200 ml aceton:vann (3:1) og tilsatt 5 g p-toluensulfonsyre. Blandingen ble oppvarmet under tilbakeløpskjøling og omrøring i 2 dager, hvoretter oppløsningen ble avkjølt til romtemperatur og fordelt mellom 1 liter dietyleter og 200 ml saltoppløsning.
Den organiske fase ble fraskilt, vasket suksessivt med natriumbikarbonatoppløsning og saltvann, tørket over vannfri magnesiumsulfat og konsentrert. Den resulterende olje ble oppløst i en minimal mengde varm isopropyleter. Krystallene som oppsto ved avkjøling ble frafiltrert for å gi 36,8 g 5-(4-fluorfenyl)-2-(1-metyletyl)-1-(3-oksopropyl)-N,4-difenyl-lH-pyrrol-3-karboksamid. En ytterligere fraksjon på 9,8 g krystaller ble oppnådd fra moderluten.
Analyse for C29H27FN2O3:
Beregnet: C, 76,63%; H, 5,99%; N, 6,16%;
Funnet: C, 76,48%; H, 6,20%; N, 6,14%.
Trinn G. Fremstilling av 2-(4-fluorfenyl)-S-hydroksy-5-(1-metyletyl)-P-okso-3-fenyl-4-[fenylamino)-karbonyl]-lH-pyrrol-l-heptansyre, metylester
En oppløsning av metylacetoacetat (26,4 ml, 243 mmol) i
250 ml vannfri tetrahydrofuran ble dråpevis tilsatt til en omrørt suspensjon av heksan-vasket natriumhydrid (6,4 g,
267 mmol) i 200 ml tetrahydrofuran ved 0°C. Etter endt gassutvikling ble 97,2 ml 2,5M n-butyllitium dråpevis tilsatt i løpet av 60 minutter.
Den resulterende oppløsning ble omrørt i 30 minutter ved 0°C og deretter avkjølt til -78°C, hvorpå en oppløsning av 36,8 g (80,9 mmol) 5-4-fluorfenyl)-2-(1-metyletyl)-1-(3-oksopropyl)-N,4-difenyl-lH-pyrrol-3-karboksamid fra Trinn F i 100 ml tetrahydrofuran ble tilsatt i løpet av 30 minutter. Den resulterende oppløsning ble omrørt i 30 minutter ved -78°C og deretter oppvarmet til 0°C hvor den ble holdt i ytterligere 60 minutter.
Blandingen ble deretter surgjort ved dråpevis tilsetning av 3 00 ml iskald 3M saltsyre, fortynnet med eter, vasket suksessivt med vann og saltvann, tørket over vannfri magnesiumsulfat og konsentrert. Hurtigkromatografi (flash chrornatography) av residuet førte til 37,9 g 2-(4-fluorfenyl)-S-hydroksy-5-(1-metyletyl)-P-okso-3-fenyl-4-[(fenylamino)karbonyl]-lH-pyrrol-1-heptansyre, metylester.
Det 90 MHz protonmagnetiske resonansspektrum av produktet oppviste signaler ved 1,50 (dublett, 6H, J=7Hz); 1,8 (multiplett, 2H); 2,45 (dublett, 2H, J=7Hz); 2,8 (bred, 1H); 3,33 (singlett, 2H); 3,5 (multiplett, 1H); 3,67 (singlett, 3H); 3,8-4,0 (multiplett, 2H); og 6,8-7,3 (multiplett, 14H) ppm mot lavere felt fra tetrametylsilan.
Trinn H. Fremstilling av R*,R*-2-(4-fluorfenyl-P,S-dihydroksy-5-(1-metyletyl)-3-fenyl-4-[(fenylamino)karbonyl]-1H-pyrrol-l-heptansyre og trans-5-(4-fluorfenyl)-2-(1-metyletyl)-N,4-difenyl-1-[2-(tetrahydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-lH-pyrrol-3-karboksamid
Luft (60 ml) ble via en sprøyte boblet gjennom en oppløsning av 2-(4-fluorfenyl)-S-hydroksy-5-(1-metyletyl)-p<->okso-3-fenyl-4-[(fenylamino)karbonyl]-lH-pyrrol-l-heptansyre, metylester (48 g, 84,1 mmol) og 92,5 ml IM tributylboran i 100 ml vannfri tetrahydrofuran. Blandingen ble omrørt over natten ved romtemperatur og deretter avkjølt til -78°C. Natriumborhydrid (3,85 g, 101,8 mmol) ble tilsatt i én porsjon til den avkjølte blandingen. Blandingen fikk oppvarmes til 0°C i løpet av 3
timer og i løpet av denne periode forekom kraftig gassutvikling.
Tørris-acetonbadet for reaksjonskolben ble erstattet med et isbad, og blandingen ble dråpevis tilsatt 18,3 ml iseddik og deretter 2 04 ml 3M vandig natriumhydroksydoppløsning og 3 0,5 ml 3 0% vandig hydrogenperoksydoppløsning.
Blandingen ble kraftig omrørt mens den i løpet av natten fikk anta romtemperatur. Blandingen ble fordelt mellom dietyleter og vann og det vandige lag fraskilt, surgjort og ekstrahert med etylacetat.
Etylacetatekstraktet ble vasket med saltvann, tørket og inndampet for å gi rå R<*>,R<*->2(4-fluorfenyl)-<p>,S-dihydroksy-5-(1-metyletyl)-3-fenyl-4-[(fenylamino)karbonyl]-lH-pyrrol-1-heptansyre som ble benyttet uten videre rensing.
Den rå syren ble tatt opp i toluen og laktonringen sluttet ved oppvarming under tilbakeløpskjøling i 6 timer. Denne blanding ble deretter kromatografert for å gi 30 g trans-5-(4-fluorfenyl)-2-(1-metyletyl)-N,4-difenyl-1-[2-(tetrahydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-lH-pyrrol-3-karboksamid som et skumaktig faststoff, smp. 90-97°C.
Analyse for C33<H>33FN2O4:
Beregnet: C, 73,31%; H, 6,15%; N, 5,18%;
Funnet: C, 73,46%; H, 6,31%; N, 5,28%.
Dette materialet besto ifølge HPLC-analyse av cis- og trans-isomerene av produktet i molforholdet 9:1. Omkrystallisasjon fra toluen-etylacetat førte til den tilnærmet rene trans-form, smp. 148-149°C.
Eksempel 2
Fremstilling av R*, R*- 2-( 4- fluor- fenyl- P. S- dihydroksv- 5-( 1- metyletyl)- 3- fenyl- 4- f( fenylamino) karbonyl]- lH- pyrrol-1- heptansyre. natriumsalt
En blanding av trans-5-(4-fluorfenyl)-2-(1-metyletyl)-N,4-difenyl-1-[2-(tetrahydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-lH-pyrrol-3-karboksamid (10 g, 18,5 mmol) og 0,74 g (18,5 mmol) natriumhydroksyd i 90 ml av en l:2-blanding av tetrahydrofuran-vann ble avkjølt til 0°C. Blandingen fikk langsomt oppvarmes til 25°C, hvorpå den ble konsentrert og det gjenværende faststoff tørket under vakuum.
Infrarødt spektreret av produktet viste hovedabsorbsjons-stopper ved 3400, 1651, 1598, 1565, 1511, 1438, 1412, 1316, 1224, 1159, 844, 754 og 702 cm"<1>.
Det 90 MHz protonmagnetiske resonansspektrum i en heksa-deutero-dimetylsulfoksydoppløsning av produktet viste signaler ved 1,34 (dublett, J=7Hz, 6H); 1,5 (multiplett, 4H); 1,80 (dublett av dubletter, J=15, 8Hz, 1H); 1,99 (dublett av dubletter, J=15, 4Hz, 1H); 3-4 (multiplett, 8H); 6,9-7,3 (multiplett, 12H); 7,50 (dublett, J=8Hz, 2H); og 9,85 (singlett, 1H) ppm mot lavere felt fra tetrametylsilan.
Eksempel 3 og 4
Fremstilling av trans- 2-( 4- flurofenyl)- N. 4- difenyl- l- r2-( tetrahvdro- 4- hvdroksy- 6- okso- 2H- pyran- 2- vl) etyl]- 5-( trifluormetyl)- pyrrol- 3- karboksamid og trans- 5-( 4- fluorfenyl)-N, 4- difenyl- 1- f 2-( tetrahydro- 4- hydroksy- 6- okso- 2H- pyran- 2-yl) etyl]- 2-( trifluormetyl) pyrrol- 3- karboksamid
Trinn A. Fremstilling av a-[[2-(1,3-dioksalan-2-yl)etyl]-amino]-4-fluorbenzeneddiksyre. a-[[2-(1,3-dioksalan-2-yl)etyl]amino]-4-fluorbenzeneddiksyre, etylester (36,5 g, 122,8 mmol, fremstillet som beskrevet ovenfor i Eksempel 1, Trinn A) ble oppløst i 1500 ml av en 5:1-blanding av metanol-vann sammen med 7,6 g natriumhydroksyd. Blandingen ble oppvarmet under tilbakeløpskjøling i 2,5 timer, hvorpå oppløsningsmidlene ble fjernet under vakuum.
Det faste residuum ble tatt opp i 325 ml vann og en blanding av 14 ml iseddik i 28 ml vann ble tilsatt under omrøring. Etter omrøring i 1 time ble ytterligere 3 ml iseddik tilsatt, og blandingen ble avkjølt i 75 minutter. Faststoffene ble oppsamlet ved filtrering, vasket med vann og så med etylacetat og deretter tørket for å gi ot-[ [2-(l,3-dioksalan-2-yl)etyl]amino]-4-fluorbenzeneddiksyre, smp. 218-220°C.
Trinn B. Fremstilling av en blanding av 5-(4-fluorfenyl)-1-(3-oksopropyl)-N,4-difenyl-2-(trifluormetyl)-1H-pyrrol-3-karboksamid og 2-(4-fluorfenyl)-1-(3-oksopropyl)-N,4-difenyl-5-(trifluormetyl)-lH-pyrrol-3-karboksamid
a~[[2-(1,3-dioksalan-2-yl)etyl]amino]-4-fluorbenzeneddiksyre (6,06 g, 22,5 mmol) ble oppløst i 45 ml trifluoreddiksyre-anhydrid og 7,47 g (33,8 mmol) N,3-difenyl-2-propynamid (fremstillet som beskrevet i Eksempel 1, Trinn D) ble tilsatt. Den resulterende blanding ble kokt under tilbakeløpskjøling i 5,5 timer. Blandingen ble deretter avkjølt, tilsatt 1,74 ml trifluoreddiksyre, hvorpå blandingen ble omrørt over natten.
Overskudd av trifluoreddiksyre-anhydrid ble fjernet under vakuum og vann ble tilsatt etterfulgt av nok aceton til å gi en homogen oppløsning. Oppløsningen ble omrørt ved romtemperatur i 3 timer. Blandingen ble tilsatt en krystallisasjonskime av N,3-difenyl-2-propynamid, hvorved det oppsto et bunnfall. Etter 3
timer ble bunnfallet fjernet ved filtrering.
Acetonet ble fjernet fra filtratet under vakuum og det faste residuum tatt opp i eter, vasket suksessivt med to porsjoner vann, to porsjoner natriumbikarbonatoppløsning og to porsjoner saltvann, og deretter tørket over vannfri magnesiumsulfat. Eteren ble fjernet under vakuum for å gi en råblanding av de to tittelforbindelsene.
Blandingen ble separert ved kolonnekromatografi på 600 g silikagel under eluering med en 4:l-blanding av heksan-etylacetat.
Den først eluerte fraksjon var 5-(4-fluorfenyl)-1-(3-oksopropy1)-N,4-di fenyl-2-(tri fluormetyl)-lH-pyrrol-3-karboksamid.
Det 90 MHz protonmagnetiske resonansspektrum i en oppløsning av deuterokloroform av dette materialet viste signaler ved 2,73 (triplett, J=7Hz, 2H); 4,21 (triplett, J=7Hz, 2H); 6,7-7,3 (multiplett, 5H); 7,40 (singlett, 5H); og 9,43 (singlett, 1H) ppm mot lavere felt fra tetrametylsilan.
Den andre eluerte forbindelse fra kolonnen var 2-(4-fluorfenyl)-1-(3-oksopropyl)-N,4-difenyl-5-(trifluormetyl)-1H-pyrrol-3-karboksamid.
Det 90 MHz protonmagnetiske resonansspektrum i en oppløsning av deuterokloroform av dette materialet viste signaler ved 2,67 (triplett, J=7Hz, 2H); 4,25 (triplett, J=7Hz, 2H); 7,0-7,3 (multiplett, 14H); og 9,4 3 (singlett, 1H) ppm mot lavere felt fra tetrametylsilan.
Trinn C: Fremstilling av trans-2-(4-fluorfenyl)-N,4-difenyl)-1[2-(tetrahydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-5-(trifluormetyl)-pyrrol-3-karboksamid og trans-5-(4-fluorfenyl)-N,4-difenyl-1-[2-(tetrahydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-2-(trifluormetyl)-pyrrol-3-karboksamid
Ved bruk av de generelle fremgangsmåtene beskrevet i Eksempel 1, Trinn G og H ble tittelforbindelsene fremstillet fra aldehyd-forbindelsene i dette eksempel, Trinn B.
Elementanalyse for de to tittelforbindelsene Var:
For trans-5-(4-fluorfenyl)-N,4-difenyl-1-[2-(tetrahydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-2-(trifluormetyl)-pyrrol-3-karboksamid:
Analyse for C31H2 6N2°4:
Beregnet: C, 65,72% H, 4,63%; N, 4,94%;
Funnet: C, 65,82%; H, 4,91%; N, 4,69%.
Trans-2-(4-fluorfenyl)-N,4-difenyl-1-[2-(tetrahydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-5-(trifluormetyl)-pyrrol-3-karboksamid inneholdt etter omkrystallisasjon fra toluen,
0,25 mol toluen som oppløsningsmiddel ved krystallisasjon, smp. 106-111°C.
Analyse for C3^26^04 • 0 ,25 C7H8 : Beregnet: C, 66,72%; H, 4,79%; N, 4,72%;
Funnet: C, 66,81%; H, 4,86%; N, 4,60%.
Claims (4)
1. Analogifremgangsmåte for fremstilling av en terapeutisk aktiv forbindelse med strukturformel I
hvor X er -CH2-, -CH2CH2-, -CH2CH2CH2- eller -CH2CH(CH3)-;
Ri er fenyl substituert med fluor, klor eller brom;
trifluormetyl; eller alkyl med 1-4 karbonatomer;
den ene av R2 eller R3 er -CONHPh, og den andre er fenyl; R4 er alkyl med 1-6 karbonatomer; eller triflurometyl;
eller en hydroksysyre eller farmasøytisk akseptable salter derav, oppnådd ved åpning av laktonringen i forbindelsene med formel I,
karakterisert ved følgende trinn: a) omsetning av en substituert [(pyrrol-l-yl)alkyl]aldehyd-
forbindelse med formel
hvor X, R!, R2, R3 og R4 er som ovenfor angitt,
med dilitium eller natrium-litiumsaltet av metylacetoacetat for
å danne en forbindelse med strukturen
hvor X, Rlf R2 , R3 og R4 er som ovenfor angitt; b) reduksjon av produktet fra trinn a) med en trialkylboran-forbindelse, så som tributylboran i nærvær av natriumborhydrid i et inert oppløsningsmiddel; c) oksydasjon av produktet fra trinn b) med alkalisk vandig hydrogenperoksydoppløsning for å fremstille en forbindelse med
formel
hvor X, R1( R2, <R>3 og R4 er som ovenfor angitt,
og d) cyklisering av produktet fra trinn c) til et lakton med formel I ved oppvarming i et egnet inert oppløsningsmiddel så som toluen, eller alternativt, ved omdannelse av produktet fra trinn c) til et farmasøytisk akseptabelt salt etter konvensjonelle metoder.
2. Fremgangsmåte ifølge krav 1, for fremstilling av trans-(±)-5-(4-fluorfenyl)-2-(1-metyletyl)-N,4-difenyl-1-[2-(tetra-hydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-lH-pyrrol-3-karboksamid,
karakterisert ved at det benyttes korresponderende utgangsmaterialer.
3. Fremgangsmåte ifølge krav 1, for fremstilling av trans-2-(4-fluorfenyl)-N,4-difenyl-1-[2-(tetrahydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-5-trifluormetyl-lH-pyrrol-3-karboksamid, karakterisert ved at det benyttes korresponderende utgangsmaterialer.
4. Fremgangsmåte ifølge krav 1, for fremstilling av trans-5-(4-fluorfenyl)-N,4-difenyl-1-[2-(tetrahydro-4-hydroksy-6-okso-2H-pyran-2-yl)etyl]-2-trifluormetyl-lH-pyrrol-3-karboksamid, karakterisert ved at det benyttes korresponderende utgangsmaterialer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/868,867 US4681893A (en) | 1986-05-30 | 1986-05-30 | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
Publications (4)
Publication Number | Publication Date |
---|---|
NO872259D0 NO872259D0 (no) | 1987-05-29 |
NO872259L NO872259L (no) | 1987-12-01 |
NO168645B true NO168645B (no) | 1991-12-09 |
NO168645C NO168645C (no) | 1992-03-18 |
Family
ID=25352470
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO872259A NO168645C (no) | 1986-05-30 | 1987-05-29 | Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-6-(2-(3-eller 4-karboksamido-substituert-pyrrol-1-yl)alkyl)-4-hydroksypyran-2-on-derivater |
NO1997012C NO1997012I1 (no) | 1986-05-30 | 1997-10-09 | Atorvastatin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO1997012C NO1997012I1 (no) | 1986-05-30 | 1997-10-09 | Atorvastatin |
Country Status (23)
Country | Link |
---|---|
US (1) | US4681893A (no) |
EP (1) | EP0247633B1 (no) |
JP (1) | JPH0757751B2 (no) |
KR (1) | KR940001006B1 (no) |
AT (1) | ATE60602T1 (no) |
AU (1) | AU601981B2 (no) |
CA (1) | CA1268768A (no) |
DE (2) | DE3767770D1 (no) |
DK (1) | DK171588B1 (no) |
ES (1) | ES2019899T4 (no) |
FI (1) | FI88617C (no) |
GR (1) | GR3001415T3 (no) |
HK (1) | HK119493A (no) |
IE (1) | IE60014B1 (no) |
LU (1) | LU90147I2 (no) |
MX (1) | MX9203095A (no) |
NL (1) | NL970034I2 (no) |
NO (2) | NO168645C (no) |
NZ (1) | NZ220409A (no) |
PH (2) | PH24661A (no) |
PT (1) | PT84975B (no) |
SA (1) | SA99200199A (no) |
ZA (1) | ZA873438B (no) |
Families Citing this family (346)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851427A (en) * | 1985-10-25 | 1989-07-25 | Sandoz Pharm. Corp. | Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use |
US4898949A (en) * | 1987-02-25 | 1990-02-06 | Bristol-Myers Company | Intermediates for the preparation of antihypercholesterolemic tetrazole compounds |
US4897490A (en) * | 1987-02-25 | 1990-01-30 | Bristol-Meyers Company | Antihypercholesterolemic tetrazole compounds |
NO881411L (no) * | 1987-04-14 | 1988-10-17 | Bayer Ag | Substituerte pyrroler. |
DE3722806A1 (de) * | 1987-07-10 | 1989-01-19 | Hoechst Ag | 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte |
US4997837A (en) * | 1987-09-08 | 1991-03-05 | Warner-Lambert Company | 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
US4906624A (en) * | 1987-09-08 | 1990-03-06 | Warner-Lambert Company | 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
EP0308736A3 (en) * | 1987-09-12 | 1990-02-14 | Nissan Chemical Industries Ltd. | Pyrimidine type mevalonolactones |
US4946963A (en) * | 1987-11-13 | 1990-08-07 | The University Of North Carolina At Chapel Hill | Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones |
US4761419A (en) * | 1987-12-07 | 1988-08-02 | Warner-Lambert Company | 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
DE3741509A1 (de) * | 1987-12-08 | 1989-06-22 | Hoechst Ag | Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte |
US4868185A (en) * | 1987-12-10 | 1989-09-19 | Warner-Lambert Company | 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
US4939143A (en) * | 1987-12-21 | 1990-07-03 | Rorer Pharmaceutical Corporation | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
US4904692A (en) * | 1987-12-21 | 1990-02-27 | Rorer Pharmaceutical Corporation | Novel HMG-CoA reductase inhibitors |
US4892884A (en) * | 1987-12-21 | 1990-01-09 | Rorer Pharmaceutical Corporation | Novel hmg-coa reductase inhibitors |
US5001128A (en) * | 1987-12-21 | 1991-03-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | HMG-COA reductase inhibitors |
US4904691A (en) * | 1987-12-21 | 1990-02-27 | Rorer Pharmaceutical Corporation | Novel HMG-CoA reductase inhibitors |
US4900754A (en) * | 1987-12-21 | 1990-02-13 | Rorer Pharmaceutical Corp. | HMG-COA reductase inhibitors |
US5001144A (en) * | 1987-12-21 | 1991-03-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
DE3800785A1 (de) * | 1988-01-09 | 1989-07-20 | Hoechst Ag | Substituierte 7-(pyridazin-5-yl)-3,5-dihydroxyheptan(en)- saeuren, ihre entsprechenden (delta)-lactone bzw. derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte |
US5173495A (en) * | 1988-01-20 | 1992-12-22 | Bayer Aktiengesellschaft | 7-[(2,6-dialkyl-4-furyl or thienyl-pyridyl)]-3,5-di-(dihydroxy-6-enoates) useful for treating circulatory diseases |
US5470982A (en) * | 1988-01-20 | 1995-11-28 | Bayer Aktiengesellschaft | Disubstituted pyridines |
NO890046L (no) * | 1988-01-20 | 1989-07-21 | Bayer Ag | Disubstituerte pyridiner. |
NO177005C (no) * | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
DE3826814A1 (de) * | 1988-08-06 | 1990-02-08 | Hoechst Ag | Neue 6-fluor-3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte |
US5010205A (en) * | 1988-08-23 | 1991-04-23 | Bristol-Myers Company | Antihypercholesterolemic tetrazol-1-yl intermediates |
US4999366A (en) * | 1988-10-31 | 1991-03-12 | The North Carolina Central Univ. | Isoxazolidine-3,5-diones, pharmaceutical compositions and method of treatment |
US5026698A (en) * | 1988-11-02 | 1991-06-25 | Nissan Chemical Industries, Ltd. | Thienopyridine type mevalonolactones |
US4957940A (en) * | 1988-12-21 | 1990-09-18 | Warner-Lambert Company | Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis |
US4906657A (en) * | 1988-12-21 | 1990-03-06 | Warner-Lambert Company | Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis |
US5132312A (en) * | 1989-03-27 | 1992-07-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US4992429A (en) * | 1989-08-24 | 1991-02-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Novel HMG-COA reductase inhibitors |
US5034409A (en) * | 1990-02-13 | 1991-07-23 | Bristol-Myers Squibb Company | Pyrrole carboxylic acids and esters for blood platelet aggregation inhibition |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5288928A (en) * | 1990-12-21 | 1994-02-22 | Ciba-Geigy Corporation | Asymmetrical hydrogenation |
WO1992019240A1 (en) * | 1991-05-01 | 1992-11-12 | University Of New Mexico | Treatment of aberrant cellular states with biomodulators |
WO1992019239A1 (en) * | 1991-05-01 | 1992-11-12 | University Of New Mexico | Treatment of aberrant cellular states with biomodulators |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
ATE178794T1 (de) * | 1993-01-19 | 1999-04-15 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5385929A (en) * | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
GT199800127A (es) | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
US6177121B1 (en) | 1997-09-29 | 2001-01-23 | Purdue Research Foundation | Composition and method for producing low cholesterol eggs |
US20080275104A1 (en) * | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US20080213378A1 (en) * | 1998-10-01 | 2008-09-04 | Elan Pharma International, Ltd. | Nanoparticulate statin formulations and novel statin combinations |
US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
HN2000000050A (es) | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | Sal mutua de amlodipino y atorvastatina |
EP1180102B9 (en) | 1999-05-27 | 2005-03-02 | Pfizer Products Inc. | Mutual prodrugs of amlodipine and atorvastatin |
SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
WO2001015674A2 (en) * | 1999-08-30 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
ATE288893T1 (de) * | 1999-11-17 | 2005-02-15 | Teva Pharma | Polymorphe form von atorvastatin-calcium |
EP1242373B1 (en) * | 1999-12-17 | 2006-03-15 | Pfizer Science and Technology Ireland Limited | A process for producing crystalline atorvastatin calcium |
HUP0203708A3 (en) | 1999-12-17 | 2003-11-28 | Warner Lambert Res & Dev Ie | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
CO5251465A1 (es) * | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
CN1535139A (zh) | 2000-11-03 | 2004-10-06 | ������ҩ��ҵ����˾ | 阿伐他丁半钙形式ⅶ |
US6737430B2 (en) | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
GB0027410D0 (en) * | 2000-11-09 | 2000-12-27 | Pfizer Ltd | Mutual prodrug of amlodipine and atorvastatin |
KR100877165B1 (ko) | 2000-11-16 | 2009-01-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 수산화 칼슘을 이용한[R(R*,R*)]-2-(4-플루오로페닐)-β,δ-디하이드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카보닐]-1H-피롤-1-헵탄산 에스테르의 가수분해 |
US6777552B2 (en) | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
LT5196B (lt) | 2000-11-30 | 2005-02-25 | Teva Pharmaceutical Industries Ltd. | Naujos atorvastatino pusiau kalcio kristalinės formos ir jų gavimo būdai, taip pat ir nauji kitų formų gavimo būdai |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
US6476235B2 (en) | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
EP1728785A1 (en) * | 2001-01-09 | 2006-12-06 | Warner-Lambert Company LLC | 7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) * | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
ATE318272T1 (de) | 2001-04-11 | 2006-03-15 | Bristol Myers Squibb Co | Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren |
AP1571A (en) | 2001-06-29 | 2006-02-10 | Warner Lambert Co | Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
GB0116212D0 (en) * | 2001-07-03 | 2001-08-29 | Avecia Ltd | Process |
DE10135013A1 (de) * | 2001-07-18 | 2003-01-30 | Bayer Ag | Herstellung von Pyridylverbindungen |
US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
EP1572638A4 (en) * | 2001-08-31 | 2010-05-05 | Morepen Lab Ltd | IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS CALCIUM ATORVASTATIN SALT (2: 1) |
US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
KR20040054729A (ko) * | 2001-10-18 | 2004-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도 |
US6806381B2 (en) * | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
EP1443919A4 (en) * | 2001-11-16 | 2006-03-22 | Bristol Myers Squibb Co | DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES |
US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
CA2469435A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
CA2475123A1 (en) * | 2002-02-19 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Desolvating solvates of atorvastatin hemi-calcium |
EP2266590A3 (en) | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
DE10212492B4 (de) * | 2002-03-21 | 2012-02-02 | Daimler Ag | Kolbenpumpe |
AU2003226051A1 (en) * | 2002-04-16 | 2003-11-03 | Banyu Pharmaceutical Co., Ltd. | Solid forms of salts with tyrosine kinase activity |
ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
JP4478563B2 (ja) * | 2002-05-14 | 2010-06-09 | プレゼント インヴェストメンツ エルエルシー | 送信信号の形成方法 |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
US7763278B2 (en) * | 2002-06-10 | 2010-07-27 | Elan Pharma International Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
US7078430B2 (en) * | 2002-07-08 | 2006-07-18 | Ranbaxy Laboratories Limited | HMG CoA-reductase inhibitors |
US20060211761A1 (en) * | 2002-07-08 | 2006-09-21 | Yatendra Kumar | Hmg-coa-reductase inhibitors |
CA2494269A1 (en) * | 2002-08-06 | 2004-02-19 | Warner-Lambert Company Llc | Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
EP1562583A1 (en) * | 2002-09-03 | 2005-08-17 | Morepen Laboratories Ltd. | Atorvastatin calcium form vi or hydrates thereof |
US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
ES2344057T3 (es) * | 2002-10-23 | 2010-08-17 | Bristol-Myers Squibb Company | Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina. |
HRP20020885B1 (en) * | 2002-11-11 | 2007-05-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A |
US7098235B2 (en) * | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
US20040102511A1 (en) * | 2002-11-21 | 2004-05-27 | Jitendra Sattigeri | Substituted pyrrole derivatives |
US20040198800A1 (en) * | 2002-12-19 | 2004-10-07 | Geoffrey Allan | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents |
JP2006513186A (ja) | 2002-12-20 | 2006-04-20 | ファイザー・プロダクツ・インク | Cetp阻害剤およびhmg−coaレダクターゼ阻害剤を含む剤形 |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
JP2006516620A (ja) * | 2003-01-24 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | 甲状腺受容体におけるシクロアルキル含有アニリドリガンド |
TW200504021A (en) * | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
JP2006520810A (ja) * | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | S−[2−([[1−(2−エチルブチル)シクロヘキシル]カルボニル]アミノ)フェニル]2−メチルプロパンチオエートの経口吸収性を増加させる方法 |
ES2377121T3 (es) * | 2003-03-17 | 2012-03-22 | Japan Tobacco Inc. | Composiciones farmacéuticas de inhibidores de CETP |
AU2004228463A1 (en) * | 2003-04-14 | 2004-10-21 | Warner-Lambert Company Llc | Process for preparing 5-(4-fluorophenyl)-1-[2-((R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
US7557143B2 (en) | 2003-04-18 | 2009-07-07 | Bristol-Myers Squibb Company | Thyroid receptor ligands |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
US20050182125A1 (en) * | 2003-05-16 | 2005-08-18 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
EP1636183A1 (en) * | 2003-05-16 | 2006-03-22 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
WO2004105752A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives as hmg-coa reductase inhibitors |
GEP20084406B (en) * | 2003-05-30 | 2008-06-25 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US7459474B2 (en) * | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
JP2007531697A (ja) * | 2003-07-11 | 2007-11-08 | プロ−ファーマシューティカルズ,インコーポレイティド | 疎水性薬剤のデリバリーのための組成物と方法 |
US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
EP1648866A1 (en) * | 2003-07-25 | 2006-04-26 | Avecia Pharmaceuticals Limited | Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin |
US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US7250444B2 (en) * | 2003-08-11 | 2007-07-31 | Pfizer Inc. | Pyrrole-based HMG-CoA reductase inhibitors |
CN1839114A (zh) | 2003-08-21 | 2006-09-27 | 默克弗罗斯特加拿大有限公司 | 组织蛋白酶半胱氨酸蛋白酶抑制剂 |
US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
EP1663969A1 (en) | 2003-09-17 | 2006-06-07 | Warner-Lambert Company LLC | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
WO2005047297A1 (en) * | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
WO2005051298A2 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
EP1722780A4 (en) * | 2003-11-26 | 2008-12-17 | Univ Duke | METHOD FOR PREVENTING OR TREATING GLAUCOMA |
BRPI0417138A (pt) * | 2003-12-05 | 2007-02-21 | Warner Lambert Co | n-alquil-pirroles como inibidores de hmg-coa-redutase |
CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
WO2005079314A2 (en) * | 2004-02-13 | 2005-09-01 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
EP1734819A1 (en) * | 2004-03-19 | 2006-12-27 | Pro-Pharmaceuticals, Inc. | Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers |
WO2005100313A1 (en) * | 2004-04-16 | 2005-10-27 | Pfizer Products Inc. | Process for forming amorphous atorvastatin calcium |
KR20060133013A (ko) * | 2004-04-16 | 2006-12-22 | 워너-램버트 캄파니 엘엘씨 | 신규 이미다졸 |
CA2649054A1 (en) * | 2004-05-05 | 2005-11-10 | Pfizer Products Inc. | Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid |
JP4579920B2 (ja) * | 2004-06-24 | 2010-11-10 | 興和株式会社 | アトルバスタチン外用剤組成物 |
US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
US7786163B2 (en) * | 2004-07-12 | 2010-08-31 | Forest Laboratories Holdings Limited (BM) | Constrained cyano compounds |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
MX2007000765A (es) | 2004-07-20 | 2007-03-28 | Warner Lambert Co | Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1). |
PT1773768T (pt) * | 2004-07-30 | 2018-11-30 | Exelixis Inc | Derivados de pirrol como agentes farmacêuticos |
EP1773128A2 (en) * | 2004-08-02 | 2007-04-18 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
WO2006021968A1 (en) * | 2004-08-26 | 2006-03-02 | Biocon Limited | PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
ES2263407T1 (es) * | 2004-09-28 | 2006-12-16 | Teva Pharmaceutical Industries Ltd | Procedimiento para la preparacion de formas de atorvastatina calcica sustancialmente libres de impurezas. |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
CA2582087A1 (en) * | 2004-10-18 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
NZ554541A (en) | 2004-10-28 | 2011-01-28 | Warner Lambert Co | Process for forming amorphous atorvastatin |
EP1814541A4 (en) | 2004-11-22 | 2009-10-28 | Dexcel Pharma Technologies Ltd | STABLE ATORVASTATIN FORMULATIONS |
CA2590533C (en) * | 2004-11-23 | 2010-09-07 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
WO2006059224A1 (en) * | 2004-12-02 | 2006-06-08 | Warner-Lambert Company Llc | Pharmaceutical compositions of amorphous atorvastatin and process for preparing same |
WO2006062876A2 (en) | 2004-12-09 | 2006-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
JP2008524159A (ja) * | 2004-12-15 | 2008-07-10 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | NEP阻害剤、内因性エンドセリン産生系の阻害剤およびHMGCoAレダクターゼ阻害剤を含有する医薬組成物 |
US7589088B2 (en) * | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7635699B2 (en) * | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
US7220859B2 (en) | 2005-01-12 | 2007-05-22 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006076597A1 (en) * | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7314882B2 (en) * | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US20060160850A1 (en) * | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
US7238702B2 (en) * | 2005-02-10 | 2007-07-03 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5HT modulators |
CA2498978A1 (en) * | 2005-02-28 | 2006-08-28 | Apotex Pharmachem Inc. | An improved process for the preparation of atorvastatin and intermediates |
CA2499047A1 (en) * | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
PT1855674E (pt) | 2005-03-02 | 2014-10-08 | Merck Canada Inc | Composição para a inibição de catepsina k |
GB2424880A (en) * | 2005-04-06 | 2006-10-11 | Generics | Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
CN101282991A (zh) * | 2005-05-26 | 2008-10-08 | 布里斯托尔-迈尔斯斯奎布公司 | N-端修饰的胰高血糖素样肽-1受体调节剂 |
US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US20060287342A1 (en) * | 2005-06-17 | 2006-12-21 | Mikkilineni Amarendra B | Triazolopyrimidine heterocycles as cannabinoid receptor modulators |
US7629342B2 (en) * | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7317012B2 (en) * | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7572808B2 (en) * | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
EP1919466B9 (en) | 2005-07-11 | 2012-05-16 | Cortria Corporation | Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative |
EP1910361A2 (en) * | 2005-07-28 | 2008-04-16 | Brystol-Myers Squibb Company | Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
GB0613567D0 (en) * | 2006-07-07 | 2006-08-16 | Arrow Int Ltd | Crystalline sodium atorvastatin |
GB0613566D0 (en) * | 2006-07-07 | 2006-08-16 | Arrow Int Ltd | Crystalline sodium atorvastatin |
CA2619486C (en) * | 2005-08-15 | 2015-05-12 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
BRPI0614280A2 (pt) * | 2005-08-15 | 2009-08-04 | Arrow Int Ltd | atorvastatina sódica cristalina e amorfa |
US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
CA2621506A1 (en) * | 2005-09-09 | 2007-03-15 | Pfizer Science And Technology Ireland Limited | Preparation of an atorvastatin intermediate |
WO2007029217A1 (en) * | 2005-09-09 | 2007-03-15 | Pfizer Science And Technology Ireland Limited | Preparation of an atorvastatin intermediate |
DE602005013007D1 (de) * | 2005-09-10 | 2009-04-09 | Ulkar Kimya Sanayii Ve Ticaret | Verfahren zur herstellung von lactonen |
WO2007035395A2 (en) * | 2005-09-16 | 2007-03-29 | Virginia Commonwealth University Intellectual Property Foundation | Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
AR056155A1 (es) * | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
EP1943215A2 (en) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
EP1923057A1 (en) | 2005-11-21 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Atorvastatin pharmaceutical formulation |
EP1808162A1 (en) | 2005-11-21 | 2007-07-18 | Teva Pharmaceutical Industries Ltd. | Atorvastatin pharmaceutical formulation |
DK1957452T3 (da) * | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium |
RU2395280C2 (ru) * | 2005-11-21 | 2010-07-27 | Тева Фармасьютикл Индастриес Лтд. | Фармацевтическая лекарственная форма аторвастатина |
KR20100023059A (ko) * | 2005-12-13 | 2010-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법 |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
EP1976873A2 (en) * | 2006-01-11 | 2008-10-08 | Brystol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
US7553836B2 (en) * | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
CN101395132A (zh) * | 2006-03-01 | 2009-03-25 | 特瓦制药工业有限公司 | 制备阿托伐他汀半钙的晶形的方法 |
WO2008020314A2 (en) * | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
ES2654847T3 (es) | 2006-04-19 | 2018-02-15 | Novartis Ag | Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R |
US20070254897A1 (en) * | 2006-04-28 | 2007-11-01 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of cardiovascular disease |
US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
ES2376396T3 (es) | 2006-06-26 | 2012-03-13 | Amgen Inc. | Método para tratar aterosclerosis. |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US20080044326A1 (en) * | 2006-07-04 | 2008-02-21 | Esencia Co., Ltd. | Sterilizer for baby products |
EA032476B1 (ru) | 2006-07-05 | 2019-06-28 | Астразенека Аб | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ |
US7795291B2 (en) | 2006-07-07 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method |
AU2007274724B2 (en) * | 2006-07-14 | 2012-07-26 | Ranbaxy Laboratories Limited | Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2008057862A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP2109608B1 (en) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
US7834195B2 (en) * | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
WO2008102563A1 (ja) | 2007-02-23 | 2008-08-28 | Next21 K.K. | 血管攣縮の治療剤又は予防剤 |
MX2009009304A (es) | 2007-03-01 | 2009-11-18 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso. |
US20080227846A1 (en) * | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
WO2008124121A1 (en) * | 2007-04-06 | 2008-10-16 | Scidose, Llc | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
CN101795684A (zh) * | 2007-04-09 | 2010-08-04 | 赛多斯有限责任公司 | 他汀类化合物与抗肥胖药的组合 |
US20080249156A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
CN101687873A (zh) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂 |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
JP4896220B2 (ja) | 2007-04-27 | 2012-03-14 | 国立大学法人九州大学 | 肺疾患治療薬 |
US20080280970A1 (en) * | 2007-05-08 | 2008-11-13 | Czarnik Anthony W | Deuterium-enriched atorvastatin |
EP2147008A2 (en) * | 2007-05-18 | 2010-01-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
CN101754965B (zh) | 2007-05-21 | 2014-03-19 | 诺华股份有限公司 | Csf-1r抑制剂、组合物及使用方法 |
EP2581081A3 (en) | 2007-06-01 | 2013-07-31 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US20090011994A1 (en) * | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
ES2513716T3 (es) | 2007-07-26 | 2014-10-27 | Amgen, Inc | Enzimas lecitina-colesteros acitransferasa modificadas |
JP2010534722A (ja) * | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
EP2209780B1 (en) | 2007-11-01 | 2014-01-01 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof |
CA2709677C (en) * | 2007-12-21 | 2017-03-14 | Lin Zhi | Selective androgen receptor modulators (sarms) and uses thereof |
KR100850558B1 (ko) * | 2008-01-02 | 2008-08-06 | 조동옥 | 아토르바스타틴의 효율적인 제조방법 |
WO2009148709A1 (en) * | 2008-04-16 | 2009-12-10 | University Of Utah Research Foundation | Pharmacological targeting of vascular malformations |
EP2285352A2 (en) * | 2008-05-13 | 2011-02-23 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
PE20091928A1 (es) * | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
WO2009144736A1 (en) * | 2008-05-29 | 2009-12-03 | Arch Pharmalabs Limited | NOVEL PROCESS FOR THE PREPARATION OF 4-FLUORO-ALPHA-[2-METHYL -1-OXOPROPYL]-GAMMA-OXO-N-ß-DIPHENYLBENZENEBUTANAMIDE AND PRODUCTS THEREFROM |
US8071638B2 (en) * | 2008-08-14 | 2011-12-06 | Teva Pharmaceutical Industries Ltd. | Solid states of atorvastatin potassium |
EP2617414A3 (en) * | 2008-10-01 | 2013-11-06 | Novartis AG | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
EP2355812B1 (en) | 2008-11-14 | 2019-07-10 | Bomi P. Framroze | Lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis |
US8115015B2 (en) * | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
GB0904102D0 (en) | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Use of atorvastatin lactols as medicaments |
GB0904100D0 (en) | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Use of rosuvastatin lactols as medicaments |
GB0904104D0 (en) | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Atorvastatin and rosuvastatin derivatives |
WO2010111665A1 (en) | 2009-03-27 | 2010-09-30 | Bristol-Myers Squibb Company | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
TW201039815A (en) | 2009-04-13 | 2010-11-16 | Resolvyx Pharmaceuticals Inc | Compositions and methods for the treatment of inflammation |
EP2488028B1 (en) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
EP2498757A1 (en) | 2009-11-13 | 2012-09-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
HUE040486T2 (hu) | 2009-11-13 | 2019-03-28 | Astrazeneca Ab | Kétrétegû tabletta készítmények |
CA2780941C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Immediate release tablet formulations |
CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
US8592396B2 (en) | 2010-04-14 | 2013-11-26 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
IT1400310B1 (it) * | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e statine e loro uso. |
WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
AU2011276254B2 (en) | 2010-07-09 | 2016-11-03 | James Trinca Green | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制 |
KR102072631B1 (ko) | 2010-08-17 | 2020-02-03 | 시르나 쎄러퓨틱스 인코퍼레이티드 | 짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제 |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
TWI462739B (zh) | 2010-11-02 | 2014-12-01 | Univ Kaohsiung Medical | Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途 |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
TWI631963B (zh) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
US9050342B2 (en) | 2011-03-29 | 2015-06-09 | Pfizer Inc. | Beneficial effects of combination therapy on cholesterol |
US20140046059A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Process for the preparation of morpholino sulfonyl indole derivatives |
EP2726456A1 (en) | 2011-07-01 | 2014-05-07 | DSM Sinochem Pharmaceuticals Netherlands B.V. | Micronized crystals of atorvastatin hemicalcium |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
WO2013072770A2 (en) | 2011-11-15 | 2013-05-23 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
TW201329104A (zh) | 2011-12-08 | 2013-07-16 | Amgen Inc | 人類lcat抗原結合蛋白質及其治療用途 |
EP2797641B1 (en) | 2011-12-29 | 2019-07-10 | Trustees Of Tufts College | Functionalization of biomaterials to control regeneration and inflammation responses |
EP2809319B1 (en) | 2012-02-02 | 2018-04-18 | The University of Sydney | Improvements in tear film stability |
CN104244946A (zh) | 2012-04-30 | 2014-12-24 | 霍夫曼-拉罗奇有限公司 | 新制剂 |
US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
NZ707859A (en) | 2012-11-20 | 2019-03-29 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose cotransporter 1 |
ES2651347T3 (es) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Composiciones y métodos para el tratamiento del cáncer |
CN103012240B (zh) * | 2012-12-11 | 2015-05-27 | 保定市龙瑞药物技术有限责任公司 | 一种阿托伐他汀钙的制备方法 |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US9593113B2 (en) | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015051479A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
RU2692799C2 (ru) | 2013-10-08 | 2019-06-27 | Мерк Шарп И Доум Корп. | Ингибиторы цистеинпротеаз катепсинов |
CN103641764B (zh) * | 2013-11-25 | 2015-12-02 | 北京三泉医药技术有限公司 | 调节血脂的药物组合物 |
US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
WO2015120580A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
ES2822561T3 (es) | 2014-09-15 | 2021-05-04 | Univ Leland Stanford Junior | Direccionamiento a enfermedad por aneurisma modulando las vías de fagocitosis |
ES2941387T3 (es) | 2015-02-27 | 2023-05-22 | Univ Leland Stanford Junior | Terapia de combinación para el tratamiento de la ateroesclerosis |
JP2018515082A (ja) | 2015-04-30 | 2018-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 代謝障害を処置するための抗ap2抗体及び抗原結合剤 |
US10835501B2 (en) | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
WO2018191794A1 (en) * | 2017-04-20 | 2018-10-25 | Zeenar Enterprises Pty Ltd | Liquid crystalline dosage form for administering a statin |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
KR102001835B1 (ko) * | 2018-08-24 | 2019-07-19 | 대원제약주식회사 | (3r,5r)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시메틸페닐아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법, 이에 사용되는 중간체, 및 중간체의 제조방법 |
BR112021004839A2 (pt) | 2018-09-26 | 2021-06-08 | Lexicon Pharmaceuticals, Inc. | formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese |
PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
WO2021126731A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
EP4052695A1 (en) | 2021-03-05 | 2022-09-07 | Midas Pharma GmbH | Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil |
KR20230000506A (ko) | 2021-06-24 | 2023-01-03 | 주식회사 종근당 | 칸데사르탄, 암로디핀 및 아트로바스타틴을 포함하는 약제학적 복합제제 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1028570A (en) * | 1963-08-14 | 1966-05-04 | Searle & Co | D-oxasteroids and derivatives thereof |
US3407214A (en) * | 1966-04-08 | 1968-10-22 | American Home Prod | 5-hydroxy-6-oxagonan-3-ones |
US3491121A (en) * | 1968-09-17 | 1970-01-20 | American Home Prod | 13-alkyl-17-alkylamino-6-oxagonanes |
US4049495A (en) * | 1974-06-07 | 1977-09-20 | Sankyo Company Limited | Physiologically active substances and fermentative process for producing the same |
JPS5612114B2 (no) * | 1974-06-07 | 1981-03-18 | ||
DE2748825C2 (de) * | 1976-11-02 | 1986-11-27 | Sankyo Co., Ltd., Tokio/Tokyo | Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie |
JPS53147073A (en) * | 1977-05-24 | 1978-12-21 | Sankyo Co Ltd | Mevalonolactone derivatives |
JPS5559180A (en) * | 1978-10-30 | 1980-05-02 | Sankyo Co Ltd | 4-hydroxy-2-pyrone ring compound, its preparation, and remedy for hyperlipemia comprising it as active constituent |
IL60219A (en) * | 1979-06-15 | 1985-05-31 | Merck & Co Inc | Hypocholesteremic fermentation products of the hmg-coa reductase inhibitor type,their preparation and pharmaceutical compositions containing them |
US4567289A (en) * | 1979-08-17 | 1986-01-28 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
US4375475A (en) * | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
US4351844A (en) * | 1980-02-04 | 1982-09-28 | Merck & Co., Inc. | Hypocholesterolemic hydrogenation products and process of preparation |
US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
DE3722809A1 (de) * | 1987-07-10 | 1989-01-19 | Hoechst Ag | 3-desmethyl-4-fluor-mevalonsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen, ihre verwendung und zwischenprodukte |
-
1986
- 1986-05-30 US US06/868,867 patent/US4681893A/en not_active Expired - Lifetime
-
1987
- 1987-05-07 CA CA000536578A patent/CA1268768A/en not_active Expired - Lifetime
- 1987-05-11 IE IE119787A patent/IE60014B1/en active Protection Beyond IP Right Term
- 1987-05-13 ZA ZA873438A patent/ZA873438B/xx unknown
- 1987-05-18 AU AU73159/87A patent/AU601981B2/en not_active Expired
- 1987-05-22 NZ NZ220409A patent/NZ220409A/xx unknown
- 1987-05-27 DK DK271287A patent/DK171588B1/da active
- 1987-05-27 FI FI872365A patent/FI88617C/fi not_active IP Right Cessation
- 1987-05-28 PH PH35310A patent/PH24661A/en unknown
- 1987-05-29 KR KR1019870005372A patent/KR940001006B1/ko not_active IP Right Cessation
- 1987-05-29 PT PT84975A patent/PT84975B/pt unknown
- 1987-05-29 DE DE8787107847T patent/DE3767770D1/de not_active Expired - Lifetime
- 1987-05-29 DE DE1997175019 patent/DE19775019I2/de active Active
- 1987-05-29 AT AT87107847T patent/ATE60602T1/de active
- 1987-05-29 JP JP62131931A patent/JPH0757751B2/ja not_active Expired - Lifetime
- 1987-05-29 EP EP87107847A patent/EP0247633B1/en not_active Expired - Lifetime
- 1987-05-29 ES ES87107847T patent/ES2019899T4/es not_active Expired - Lifetime
- 1987-05-29 NO NO872259A patent/NO168645C/no not_active IP Right Cessation
-
1989
- 1989-12-12 PH PH39677A patent/PH26330A/en unknown
-
1991
- 1991-01-31 GR GR91400099T patent/GR3001415T3/el unknown
-
1992
- 1992-06-22 MX MX9203095A patent/MX9203095A/es unknown
-
1993
- 1993-11-04 HK HK1194/93A patent/HK119493A/xx not_active IP Right Cessation
-
1997
- 1997-09-05 NL NL970034C patent/NL970034I2/nl unknown
- 1997-10-08 LU LU90147C patent/LU90147I2/fr unknown
- 1997-10-09 NO NO1997012C patent/NO1997012I1/no unknown
-
1999
- 1999-05-31 SA SA99200199A patent/SA99200199A/ar unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO168645B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-6-(2-(3-eller 4-karboksamido-substituert-pyrrol-1-yl)alkyl)-4-hydroksypyran-2-on-derivater | |
US5385929A (en) | [(Hydroxyphenylamino) carbonyl] pyrroles | |
EP0252476B1 (en) | Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof | |
US4761419A (en) | 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis | |
US4929620A (en) | 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis | |
US4826847A (en) | Beta-blocking oxindole derivatives | |
US4735958A (en) | Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis | |
NZ213252A (en) | Trans-6-((substitutedpyrrol-1-yl)alkyl)-pyran-2-ones and pharmaceutical compositions | |
JP2011236218A (ja) | 置換ピロール誘導体 | |
US5102893A (en) | Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis | |
US4957971A (en) | Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis | |
US6025390A (en) | Heteroaromatic pentadienoic acid derivatives useful as inhibitors of bone resorption | |
EP0398413A1 (en) | "3,4-dehydropiperidine derivatives having psychotropic activity | |
US4868185A (en) | 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis | |
AU2004243247A1 (en) | Substituted pyrrole derivatives as HMG-CoA reductase inhibitors | |
AU2011211338A1 (en) | Substituted pyrrole derivatives and their use as HMG-CO inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |